BIOMAT Database Logo BIOMAT Database Logo

Abnormal agonist-stimulated cardiac parasympathetic acetylcholine release in streptozocin-induced diabetes. 1993

L Uccioli, and P Magnani, and P Tilli, and P Cotroneo, and A Manto, and A V Greco, and A A Sima, and D A Greene, and G Menzinger, and G Ghirlanda
Department of Internal Medicine, Tor Vergata University II, Rome, Italy.

We examined the effect of three distinct depolarizing conditions on [3H]ACh release from cardiac postganglionic parasympathetic neurons in age-matched controls and insulin-treated STZ-induced diabetic rats to determine whether alterations in neurotransmitter release were present in the diabetic group. The effect of TTX, which exerts a use- and voltage-dependent block of sodium channels, was examined on the release of ACh stimulated by SRIF14 (preferentially acts at the cell body). We also studied the effect of STZ-induced diabetes on [3H]ACh release by the relatively site-specific depolarizing agent VT (preferentially acts at the axon) and high potassium (non-site-specific). Basal, SRIF14-(10(-7) M), VT-(10(-4) M), and K+ (100 mM)-stimulated [3H]ACh release was similar in control and STZ-induced diabetic animals. However, in STZ-induced diabetic but not control rats, SRIF14-induced [3H]ACh release was resistant to TTX (2 x 10(-7) M). In addition, the response to submaximal K+ (25 mM) stimulation was greater in STZ-induced diabetic compared with control animals. Treatment with insulin corrected these abnormalities. These data indicate that in the acute STZ-induced diabetic rat, SRIF14-, VT-, and high K(+)-evoked release of ACH is not impaired, which suggests that the mechanisms associated with ACh storage and release in postganglionic cardiac parasympathetic neurons are not affected in this model.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D010275 Parasympathetic Nervous System The craniosacral division of the autonomic nervous system. The cell bodies of the parasympathetic preganglionic fibers are in brain stem nuclei and in the sacral spinal cord. They synapse in cranial autonomic ganglia or in terminal ganglia near target organs. The parasympathetic nervous system generally acts to conserve resources and restore homeostasis, often with effects reciprocal to the sympathetic nervous system. Nervous System, Parasympathetic,Nervous Systems, Parasympathetic,Parasympathetic Nervous Systems,System, Parasympathetic Nervous,Systems, Parasympathetic Nervous
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D000109 Acetylcholine A neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. 2-(Acetyloxy)-N,N,N-trimethylethanaminium,Acetilcolina Cusi,Acetylcholine Bromide,Acetylcholine Chloride,Acetylcholine Fluoride,Acetylcholine Hydroxide,Acetylcholine Iodide,Acetylcholine L-Tartrate,Acetylcholine Perchlorate,Acetylcholine Picrate,Acetylcholine Picrate (1:1),Acetylcholine Sulfate (1:1),Bromoacetylcholine,Chloroacetylcholine,Miochol,Acetylcholine L Tartrate,Bromide, Acetylcholine,Cusi, Acetilcolina,Fluoride, Acetylcholine,Hydroxide, Acetylcholine,Iodide, Acetylcholine,L-Tartrate, Acetylcholine,Perchlorate, Acetylcholine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone

Related Publications

L Uccioli, and P Magnani, and P Tilli, and P Cotroneo, and A Manto, and A V Greco, and A A Sima, and D A Greene, and G Menzinger, and G Ghirlanda
Presynaptic modulation of acetylcholine release from cardiac parasympathetic neurons.
January 1985, The American journal of physiology,
L Uccioli, and P Magnani, and P Tilli, and P Cotroneo, and A Manto, and A V Greco, and A A Sima, and D A Greene, and G Menzinger, and G Ghirlanda
Acetylcholine release at parasympathetic synapses.
February 1950, Acta physiologica Scandinavica,
L Uccioli, and P Magnani, and P Tilli, and P Cotroneo, and A Manto, and A V Greco, and A A Sima, and D A Greene, and G Menzinger, and G Ghirlanda
[Streptozocin-induced diabetes].
January 1998, Nihon rinsho. Japanese journal of clinical medicine,
L Uccioli, and P Magnani, and P Tilli, and P Cotroneo, and A Manto, and A V Greco, and A A Sima, and D A Greene, and G Menzinger, and G Ghirlanda
Effect of divalent cations on acetylcholine release from cardiac parasympathetic nerve endings.
October 1978, Pflugers Archiv : European journal of physiology,
L Uccioli, and P Magnani, and P Tilli, and P Cotroneo, and A Manto, and A V Greco, and A A Sima, and D A Greene, and G Menzinger, and G Ghirlanda
Streptozocin-diabetes modifies acetylcholine release from mouse phrenic nerve terminal and presynaptic sensitivity to succinylcholine.
May 1993, Japanese journal of pharmacology,
L Uccioli, and P Magnani, and P Tilli, and P Cotroneo, and A Manto, and A V Greco, and A A Sima, and D A Greene, and G Menzinger, and G Ghirlanda
Effects of streptozocin-induced diabetes on sympathetic and parasympathetic stimulation of parotid salivary gland function in rats.
November 1989, Diabetes,
L Uccioli, and P Magnani, and P Tilli, and P Cotroneo, and A Manto, and A V Greco, and A A Sima, and D A Greene, and G Menzinger, and G Ghirlanda
The mechanism of acetylcholine release from parasympathetic nerves.
July 1971, The Journal of physiology,
L Uccioli, and P Magnani, and P Tilli, and P Cotroneo, and A Manto, and A V Greco, and A A Sima, and D A Greene, and G Menzinger, and G Ghirlanda
Sudden Heart Rate Reduction Upon Optogenetic Release of Acetylcholine From Cardiac Parasympathetic Neurons in Perfused Hearts.
January 2019, Frontiers in physiology,
L Uccioli, and P Magnani, and P Tilli, and P Cotroneo, and A Manto, and A V Greco, and A A Sima, and D A Greene, and G Menzinger, and G Ghirlanda
Indomethacin in streptozocin-induced nephrogenic diabetes insipidus.
January 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation,
L Uccioli, and P Magnani, and P Tilli, and P Cotroneo, and A Manto, and A V Greco, and A A Sima, and D A Greene, and G Menzinger, and G Ghirlanda
Dynamic targeting of the agonist-stimulated m2 muscarinic acetylcholine receptor to caveolae in cardiac myocytes.
July 1997, The Journal of biological chemistry,
Copied contents to your clipboard!